Autolus Therapeutics Boosts Revenue 119% on AUCATZYL Demand
Event summary
- $45.7M Q2 revenue for AUCATZYL, up 119% YoY
- FY 2026 guidance raised to $140–$150M from $120–$135M
- Secured $250M credit facility with Perceptive Advisors
- Gross margin improved to 55% on volume growth and cost cuts
The big picture
Autolus is capitalizing on AUCATZYL's differentiated safety profile in adult relapsed/refractory B-ALL, while expanding into autoimmune indications. The $250M financing bolsters its balance sheet as it competes with CAR-T leaders like Kite and Novartis. Success hinges on maintaining operational efficiency gains amid clinical trial execution.
What we're watching
- Commercial Momentum
- Whether AUCATZYL can sustain triple-digit growth as new treatment centers come online.
- Pipeline Progress
- The pace at which obe-cel advances in lupus nephritis and progressive MS trials.
- Financial Flexibility
- How Autolus deploys the $250M credit facility to extend cash runway beyond 2028.
Related topics